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Traumatic brain injury is one of the leading causes of morbidity and mortality in the 
United States. A number of different pharmacological and therapeutic based clinical trials have 
proven to not be efficacious for reversing these trends. In fact, many of these clinical trials have 
had deleterious effects on patient outcome. Clinical trials with magnesium supplementation are 
included in this group. The routine use of magnesium may increase the likelihood of secondary 
hypoxic and anoxia events in these patients, therefore leading to increases in morbidity and 
mortality in a number of patient populations.  
The purpose of this study was to investigate the effects of magnesium supplementation 
on cerebral oxygen tension levels after closed head injury. Nineteen severe head injury patients, 
who had both cerebral oxygen probe placement and magnesium supplementation within the first 
48 hours after injury were included in this study. All interventions were performed under patient 
consent and Institutional Review Board approval. The cerebral vascular response to magnesium 
varied by patient, with some patients having dramatic loses or gains in oxygen levels, while 
others were unaffected. Since only two female patients were included in this group, statistical 
analysis of data was restricted to the males of the study group. Overall cerebral oxygen levels 
were clinically unchanged during magnesium infusion periods (27.698 mmHg versus 
24.886mmHg) using a mixed model regression adjusting for cerebral perfusion pressure, time 
after a magnesium infusion and percent of inspired oxygen (p<0.0001). An additional model was 
constructed controlling for the same variables to investigate the impact of the magnesium dose 
on tissue oxygenation.  Only doses of two or four grams of magnesium improved brain tissue 
oxygenation (β=8.980 and 8.500 respectively p< 0.001).  In conclusion magnesium infusions are 
not adversely affecting tissue oxygen levels after head injury and a dose of four grams or less 
during actually improve oxygen levels. The public health significance of this study is that the 
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routine use of intravenous magnesium supplementation may exacerbate tissue injury in patients 
with impaired blood flow to the brain. The resulting increases in the mortality and morbidity to 
brain injury patients would have an enormous economic and social cost.  
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1.0  INTRODUCTION AND SCIENTIFIC BACKGROUND 
Head injury is one of the leading causes of mortality and morbidity in the United States.  The 
major focus of post-injury treatment in head trauma victims is the reduction of secondary injuries 
to the brain in the hours and days after the initial traumatic injury.  Secondary injuries can 
propagate through the brain as mechanical and apoptotic cell deaths release ever-increasing 
amounts of biochemicals and free radicals into the neuronal environment.  These fundamental 
changes to the interstitial fluid leave neurons teetering on the edge of life and death.  Therefore, 
it is absolutely essential to optimize post-traumatic treatment to ensure adequate supplies of 
blood and oxygen to the brain tissue as a whole, and especially that tissue closest to the injury, 
termed the penumbra.   Recently, magnesium supplementation therapy has garnered attention as 
a vasodilator and neuroprotective agent after brain injury in an attempt to improve neurological 
outcomes. 
Magnesium is an essential trace metal for normal bodily and cellular function.  Bone is 
the major storehouse for magnesium in the body (Ebel 1980).  Ionized magnesium can be 
liberated from bone to the extracellular fluid, where it can be used as a cofactor in enzymatic 
reactions (Ebel 1980).  Magnesium is also essential to ATP production in cells (Ebel 1980, 
Jacobash 1977).  Since magnesium is essential for energy production, a lack of free intracellular 
magnesium can lower the cellular anabolic processes (Teraski and Rubin 1985).   
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Magnesium ions have a particularly vital role in the regulation of neuronal impulses in 
the central nervous system.  Meltzer and Auer reported the paralysis of rabbits with intracerebral 
injections of magnesium sulfate, which could be reversed by injections of calcium ions (Meltzer 
and Auer 1908).  This inhibitory effect of magnesium is a reflection of the antagonistic 
relationship magnesium and calcium share throughout the body.  It is, however, gravely 
important to normal neuronal functions.  Glutamate is a major excitatory neurotransmitter in the 
brain, and its n-methyl-d-aspartate (NMDA) receptor is blocked by magnesium (Nowak et al. 
1984 and Marrets et al.1995).  The NMDA receptor has long been theorized to be a primary 
entry point for calcium into neurons in the after trauma.  Magnesium and calcium influx can 
determine the amount of acetylcholine released from presynaptic neurons (Krapivinsky et al. 
2006).  The cellular level effects of magnesium have consequences for the entire body.  
Therefore, the interplay between calcium and magnesium ion fluctuations after brain injury is 
critical to neurological outcome.   
1.1 EXPERIMENTAL EVIDENCE 
Magnesium’s essential intracellular functions have led to a myriad of animal experiments to 
examine the magnesium response to trauma.  Bareyre et al. showed that the level of serum 
magnesium after trauma was predictive of outcome in rats (Bareyre et al. 1999).  In this 
experiment, serum magnesium depressions could safely be raised by supplementation with 
magnesium compounds without any affect to the cardiovascular system (Bareyre et al. 1999).  
Other studies have shown that magnesium injections prior to injury were associated with 
hyperglycemia, larger ATP loss, greater acidosis, and lower heart rate (Blair et al. 1989; Gee et 
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al. 2004).   When giving magnesium prior to injury, however, the dose and type of magnesium 
may influence the outcome after trauma (Miles et al. 2001).  Westermaier et al. found that pre-
injury doses of magnesium caused a transient depression in MAP and heart rate (Westermaier et 
al. 2005).    In addition, it was found that slow infusions are better than bolus infusions for the 
recovery of blood flow after experimental occlusion (Westermaier et al. 2005).  
 Intracellular magnesium loss is a hallmark of traumatic brain injury. Rat studies have 
shown that Mg2+ shows a persistent decline after trauma (Vink et al. 1988).  CSF total 
magnesium has been shown to be predictive of outcome in humans (Fischer et al. 2006).  The 
predictive value of serum and intracellular magnesium are well proven in animal and human 
models after injury (Bareyre et al. 1999; Lampl et al. 1998; Miles et al. 2001; Vink et al. 1988).  
In addition to effects on neurons, magnesium has a known influence on the cerebral vascular 
tone. 
1.2 PHYSIOLOGICAL RATIONALE FOR AND THE USE OF MAGNESIUM IN 
CLINCAL TRIALS 
Cerebral perfusion pressure (CPP) is a non-invasive measure of the pressure of blood flow 
through the entire brain.  In closed head injuries, the swelling brain has very little room to 
expand. As the brain swells into the skull, the pressures exerted on the brain tissue increase, 
providing a force acting to narrow cerebral arteries, and restrict blood flow to the tissue. 
Extraventricular drains can be used to measure and relieve pressures associated with herniation.  
CPP is calculated as the difference between the mean arterial pressure and intracranial pressure 
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at any given time point.  It has been recommended that CPP be maintained at 60mmHg or above 
in order to ensure adequate blood supply to the brain (Juul et al. 2000).   
Declines in CPP as little as 10mm Hg can affect mortality as much as twenty percent 
(Bullock et al. 1995).  As cerebral perfusion pressures fall, the risk of hypoxic insult to the brain 
increases (Marin-Caballos et. al. 2005).  Since neurons maintain ionic gradients for synaptic 
transmission, they are especially sensitive to ischemic episodes where there is a failure of 
cellular energy stores (Rothman 1983).  Magnesium supplementation has been shown to protect 
neuronal cultures from anoxia due to ischemic episodes (Rotham 1983).  Head injury patients 
with normal levels of ionized magnesium in their blood are more likely to have an improved 
neurological outcome (Stippler et al. 2006).  The biochemical and physiological effects of 
magnesium on the brain are critical in the acute post-traumatic period.  Altura et al. have shown 
that rats deficient in magnesium had greatly increased arterial pressures due to a 33% increase in 
vasoconstriction (Altura et al. 1984). This may be due to alterations in management of blood 
lipid levels, which are associated with serum magnesium levels (Atura et al. 1990)   
Lack of magnesium was associated with greater contractility of vascular smooth muscle 
cells (VSMCs) in response to norepinephrine in a dog artery model (Turalapaty and Altura 
1980).  In addition, the VSMCs of hypertensive rats have less magnesium than non-hypertensive 
rats (Touyz et al. 1998).  Even normal rats fed a magnesium deficient diet had higher 
intracellular calcium ion levels, which would allow for prolonged vasoconstriction (Touyz et al. 
1998).  Magnesium supplementation has been shown to increase cerebral oxygenation by 34 
percent after aneurysm clipping (Chan et al. 2005).   
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1.2.1 Magnesium and the Brain 
Magnesium levels in the cell are tightly regulated under normal conditions.  In the normal brain, 
the uptake of peripherally administered magnesium is sluggish (Opplet et al. 1963).  Even with 
serum magnesium levels elevated 3 to 4 times normal levels for hours there was only about a 
20% increase in magnesium in the cerebrospinal fluid (CSF) (Opplet et al. 1963).  The exchange 
between the extracellular fluid (ECF) and cells leads to a relatively constant interstitial and 
intracellular magnesium level (Romani 2006).  Once inside the cell, the divalent positive charge 
of ionized magnesium allows it to bind to negatively charged molecules. This binding leads to a 
compartmentalization of bound magnesium into organelles such as the mitochondria and 
endoplasmic reticulum (Romani 2006).  
 The depressed levels of serum magnesium after head injury have many potential causes.  
These include the use of osmotic agents (which increase renal magnesium loss) the use of 
magnesium free IV fluids and loss of blood (Polderman et al. 2000 Kahraman et al. 2003).  
Supplementation of magnesium into the blood therefore should restore normal serum magnesium 
levels, while also protecting the injured brain.   Magnesium reaches the brain slowly at best 
under normal conditions and may reach the brain in miniscule amounts under traumatic 
conditions.  McKee et al. have shown that magnesium enters the brain slowly after trauma, with 
only a fifteen percent increase after twenty-four hours of hypermagnesemia (McKee et al. 2005).  
It was also found that magnesium entry into the CNS varies according to the type of injury, with 
closed head trauma having the smallest increase (McKee et al. 2005). In a study of magnesium 
versus nimodipine in subarachnoid hemorrhage, the CSF levels of ionized magnesium were 
unaffected by supplementation (Schmid-Elsaesser et al. 2006).  Therefore, the intended purpose 
for magnesium supplementation may never be realized and the potential deleterious effects to 
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cerebral blood flow may actually make supplementation worse.  Stippler et al. have shown that 
patients with low serum magnesium levels that are corrected inside 24 hours actually do 
significantly worse than those patients who are not corrected (Stippler et al. 2006).  
1.2.2 Magnesium in Clinical Trials  
The use of magnesium as a therapeutic agent to prevent neuronal loss after traumatic injuries to 
the brain has not yet proven effective in clinical trials.  The magnesium supplementation group 
of the Magnesium and Acetylsalicylic acid in Subarachnoid Hemorrhage (MASH) trial has been 
shown to have significantly better outcomes, but supplementation did not affect the number of 
poor outcomes or delayed cerebral ischemic events (van den Berg et al. 2005).  Wong et al. have 
found that magnesium supplementation did not improve the number of good outcomes but that it 
did reduce the length of vasospastic episodes in subarachnoid hemorrhage patients (Wong et al. 
2006).  Other small randomized trials have proven that the circulatory effects of magnesium 
supplementation in stroke patients were not significantly different from placebo.  Also, the 
outcome of patients was not significantly changed (Muir et al. 1995; Muir et al. 1998).  
The largest clinical trial yet completed on magnesium therapy, the Intravenous 
Magnesium Efficacy in Stroke (IMAGES) trial, failed to show any significant change in outcome 
with magnesium.  In fact, there was a slightly higher mortality in the magnesium group (Lees et 
al. 2004).  This trial consisted of over two thousand patients and the only positive change in 
outcome was seen in a small lacunar stroke population (Lees et al. 2004).  Is magnesium therapy 
for the treatment of brain injury dead with this trial?  Arango and Mejia-Mantilla have done a 
review of all major magnesium trials and found no evidence of a benefit to magnesium 
supplementation (Arango and Mejia-Mantilla 2006).  The recently published study by Temkin et 
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al., showed magnesium supplementation to worsen neurological outcomes and increase mortality 
rates in head injury patients (Temkin et al. 2007).   
Why has magnesium supplementation been shown so effective in small clinical trials, but 
as ineffective or even deleterious in larger clinical trials?  The answer most likely relies on how 
the individual patients respond to magnesium.  As the population sampled grows, so does the 
variance in the response to magnesium supplementation.  Since vasoconstriction and pressure 
from the swelling brain will act to constrict the cerebral vasculature, a vasodilator, like 
magnesium, should improve cerebral oxygenation.  This improvement has been shown to occur 
in aneurysm patients after a brief period of vessel occlusion (Chan et al. 2005).   
1.2.3 Specific Aims 
The increases in mortality and morbidity caused by magnesium supplementation in clinical trials 
presents a conundrum for the treatment of head injury patients, who are commonly given 
magnesium in order to augment serum levels (Lees et al. 2004; Temkin et al. 2007).  Patients 
who are supplemented for serum magnesium levels below the normal range within the first 24 
hours after traumatic brain injury have significantly worse outcomes than those patients who are 
not supplemented (Stippler et al. 2006).  Given these potential problems with magnesium 
administration and its properties as a vasodilator, the purpose of this study is to investigate the 
effects magnesium infusions have cerebral oxygen levels after traumatic brain injury. 
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2.0  MATERIALS AND METHODS 
The patient population for this study consists of patients admitted to Presbyterian University 
Hospital (PUH) with a closed head injury, Glasgow Coma Score (GCS) of 8 or less and who are 
admitted to the hospital within the first 48 hours after the time of the injury (Figure 1).  In 
addition, these patients must have an extraventricular drain (EVD) placed, a Licox probe to 
measure cerebral oxygen tension, and a dose of magnesium sulfate.  A closed head injury is any 
injury not involving a penetrating foreign body. Therefore, the brain can be exposed to the 
ambient air, and patients with injuries such as depressed skull fractures will be accepted.  On the 
GCS scale, a score of 8 or less indicates a severe level of neurological impairment. A patient can 
qualify for the study if his/her GCS score upon hospital admission is 8 or less, or if the patient is 
admitted to the hospital with a GCS above 8 and later his/her condition deteriorates.  Patients in 
the latter category are usually brought in from outside hospitals and thus are unlikely to have met 
the criteria for acceptance into this study before the end of the 48 hour period.   
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 Glasgow Coma Scale (GCS): 
EYES     Open   Spontaneously:   4  
        To verbal command:  3 
        To pain:   2 
        No response:  1 
BEST MOTOR RESPONSE  To verbal command Obeys:   6 
     To painful stimulus Localizes pain:  5 
        Flexion-withdraw: 4 
        Flexion-abnormal: 3 
        Extension:  2 
        No response  1 
BEST VERBAL RESPONSE    Oriented and converses: 5 
        Disoriented and converses:4 
        Inappropriate words: 3 
        Incomprehensible sounds: 2 
        No response:  1 
       TOTAL          3-15 
Figure 1 Glasgow Coma Scale 
Glasgow Coma Scale scores for eye opening, motor response and verbal response. 
 
The initial 48 hour period after injury has been chosen since this is a critical time for 
averting secondary injuries to the brain (Bullock et al. 1995).  The significance of using this time 
period for physiological monitoring is that this is the most likely time for ischemic events, and 
magnesium therapy has been theorized as being critical in this early time period (Lees et al. 
2004).  With recent clinical studies and trials showing magnesium supplementation worsening 
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neurological outcome, the efficacy of serum magnesium replacement in the traumatic brain 
injury population needs examining (Temkin et al. 2007, Stippler et al. 2006).  Since magnesium 
is theorized to influence vasodilation at the arteriole and venuole level, tissue oxygenation should 
be directly effected by magnesium supplementation (Belfort et al. 1999).  This vasodilatory 
effect may lead to hypoperfusion and subsequent anoxic insult to the brain.  Therefore this study 
focuses on the affect of the of magnesium supplementation on Licox values in patients given 
magnesium sulfate to augment low serum magnesium levels.   
2.1 DATA SOURCES 
The data collection for this study is being achieved through the use of multiple sources.  
Presbyterian university hospital maintains secured online databases that store patient medical 
records (MARS) and bedside records of treatment on intensive care unit (ICU) patients called 
EMTEK.  In order to determine the effect magnesium has on a patient’s Licox values, the exact 
time of initiation of the medication, as well as the dose, must be obtained.  The MARS database 
lists records of every medication given, the dose, and the start time of the medication.  MARS 
relies on the bedside nurse to obtain this information and, therefore, the EMTEK records will be 
the ultimate source for medication times.  For each medication that is not given as a continuous 
infusion, the bedside nurse lists the time, type and dose of the medication.  This is done by 
scanning the admission bracelet of the patient and then the medication’s pharmacy bar code, 
which logs the information into the bedside computer.  This system minimizes the risk for 
improper dosage and medications.  The exact end time of the medication is a rough estimate, 
given the infusion rate and the volume of the medication.  Since these patients are paralyzed and 
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sedated, the route of medication administration is by intravenous (IV) access.  This may 
constitute directly syringing the medication through the central IV line or by IV bags.  
Magnesium infusions occur by the latter method.  Since magnesium is infused by bag, it is 
possible to have unrecorded periods when the medication is stopped, but the magnesium dose 
should finish fairly close the actual time prescribed by the magnesium protocol (Table 1).  
Adherence to this protocol will consist of not only the dose, but the time over which the dose is 
given.  In order to determine the proper dose, all patients will have their serum magnesium levels 
recorded, and this will be the primary determinant of whether the dose is appropriate. 






Recheck Level After 
Infusion 
1.5-1.9 4 grams Over 2 hours In AM 
1.0-1.4 8 grams Over 4 hours In AM 
<1.0 8 grams Over 4 hours 4 hours 
Magnesium replacement protocol for the neurointensive care unit at the University of Pittsburgh. 
 
MARS and EMTEK are also being used to obtain data on the patients’ care and injury 
history.  Included in the MARS database are records for ventilator settings.  Whenever there is a 
change in a patient’s ventilator care, the entire set of settings on the ventilator is recorded as well 
as the time and date.  The ventilator setting that has the most profound effect on Licox values is 
the fraction of inspired oxygen (FiO2) (Figure 2).  The viability of a Licox probe is tested, once 
it is placed in the brain tissue, by changing the FiO2 level to 100% for a short period of time and 
seeing if there is a subsequent increase in cerebral oxygen levels.  The response is often rapid, 
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thus indicating the viability of the probe, and the ventilator is reset to the original settings.  Given 
this ability of FiO2 to influence the Licox value, it is expected that some patients will be 
managed for low cerebral oxygen tension (Licox values) by manipulation of the FiO2 setting 
(Figure 3). 
 
Figure 2 Licox Placement Oblique View. 
CT scan image of Licox probe trajectory into the brain in a trauma patient. 
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 Figure 3 CT Scan of Brain with Blood Perfusion Data Shown. 
This is a CT scan of a brain tissue injury showing location of Licox (PbtO2) probe and the EVD.   The bright 
white areas in the brain are the hemorrhagic regions of the brain.  Also pictured is a Xenon CT scan showing 
areas of poor blood flow in blue. 
 
The results of all Computed Axial Tomography (CT) scans will also be obtained from 
MARS.  The radiologist’s impressions of the initial scan will be recorded and designated as the 
primary neurological injury.  The reports consist of a description of the areas of the brain 
affected and what type of injury persists in that area.  This is followed by a brief description of 
the injuries in bullet form fashion.  Both areas of these reports will be utilized, since injuries that 
are considered lesser at the time of the initial CT scan can erupt into larger injuries at a later date.  
In addition, the Marshall score will be given when available.  This score is a measure of the 
severity of the injury and is prognostic of outcome (Marshall et al. 1991).  The Marshall score 
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attempts to quantify the amount of swelling in the brain by scoring for the presence or 
compression related absence of specific anatomical brain regions (Marshall et al. 1991). 
Marshall Diagnosis Score for CT scans: 
1: No visible intracranial pathology seen on CT. 
2: Cisterns present with shift of 0-5mm/Lesion present. 
3: Cisterns compressed or absent with shift 0-5mm, no lesion >25cc. 
4: Midline shift >5mm no high or mixed density, lesions >25cc. 
5: Any lesion surgically evacuated. 
6: High or mixed density lesion >25cc, not surgically removed. 
8: Primary brain stem lesion. 
9: unknown. 
Figure 4 Marshall Score Diagnosis Scale. 
Marshall diagnosis for severity of brain trauma on CT scans. 
 
EMTEK will be used to note all times when blood transfusion are given to the patients.  
There is no evidence that blood transfusion directly influences Licox values. However, 
transfusions will increase blood volume, and therefore, impact other physiological variables like 
mean arterial pressure (MAP), CPP and possibly even intracranial pressures (ICP).  MARS 
includes no records on blood transfusions, since blood products are the obtained from the Central 
Blood Bank and not the hospital itself.  Therefore, EMTEK will be the only source for the time 
of transfusion and the number of units transfused. 
For all demographic, surgical, complications and interventions data, the Brain Trauma 
Research Center (BTRC) will be the primary source.  This database is the main database for the 
National Institute of Health grant that funds the research performed on closed head injury at 
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PUH.  All patients that come to the hospital with a GCS of 8 or less and a non-penetrating brain 
injury are assigned a University Identification Number and (UID) and general demographics are 
obtained, such as name, initial GCS and mechanism of injury.  All families of the patients are 
approached to obtain consent for study procedures, and only those patients who have family 
obtained consents were considered for this study.  
 The primary data sources for this study are demographics, surgery complications, 
emergency department records, outcome databases and physiological databases, which are part 
of the main BTRC database.  Data that are beyond the time frame or scope of this study will not 
be used, but all other data will be used to provide a detailed description of how the patient was 
injured and how the patient was cared for in the ICU.  There will be two main demographic files: 
the surgical and general demographic file.  The general demographic file will have information 
on all aspects of the patient’s background, injury history, and complications.  The surgical 
database will have detailed records of surgeries performed. The need for this separation of 
demographics is the fact that all patients are likely to have multiple surgeries on multiple organ 
systems, due to the nature of how the patients are commonly injured.  Data considered beyond 
the scale of this study are those that would not directly affect outcome or Licox values directly.  
The notable exception is the outcome database which records the Glasgow Outcome Scale 
(GOS) scores for each patient at 3, 6, 12 and 24 months (Figure5).  Since the physiological 
trends and data trends of each patient will directly portend the patient’s eventual outcome, these 
data are critical to this study.  The primary neurological outcome time will be the three month 
GOS. While patients can go up or down one point on the GOS scale as time progresses, two 
point swings in either direction are rare.  In the case of a later death, these changes are often not 
related to the head injury, but other injuries suffered in or due to the original accident.   
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 Glasgow Outcome Scale (GOS): 
1: Dead 
2: Vegetative 
3: Severely Disabled 
4: Moderately Disabled 
5: Good Recovery 
Figure 5 GOS Scale. 
 
All data on physiological parameters will be obtained from the Patient Data Server (PDS) 
arm of the main BTRC database.  Data are obtained by linking the monitors at each of the patient 
beds on the NICU to a network, where the server has access to download the data.  Data are 
downloaded and then posted to a program that cross lists all of the physiological parameters 
according to the minute they were recorded from the unit.  These data are then “cleaned” by a 
nurse to remove any spurious data that can result from normal patient activities interfering with 
the proper functioning of the various monitoring probes.  Given this restriction, there is a limited 
pool of patients available for this study.  The use of the Licox probe began in February of 2002 
and the last clean data were posted around the end of 2005.  In that time period, 154 patients 
were enrolled in the BTRC study and of those patients, 28 met the qualifications of having Licox 
probes, a valid consent, cleaned data, and being housed on a unit wired for the PDS.  Of these 28 
patients, 19 had a magnesium dose within the first 48 hours. 
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2.2 PATIENT MANAGEMENT IN THE ICU SETTING 
2.2.1 Admission Protocol 
The care of all severe head injury patients is governed by the Physician Orders.  These orders set 
up four different protocols that direct patient care from admission to discharge from the ICU.  
The first protocol covers patient hospital admission. The aim of this protocol is to maintain an 
environment for the patient so as to minimize the potential for secondary insults to the brain 
(Figure 16A).  In order to minimize this risk, the primary concern for patients placed on this 
protocol is to sustain the various physiological parameters within their prescribed ranges.  
Determining whether the protocol was followed hinges on whether the patient remains in these 
physiological ranges.  All patients will be checked to assure that the prescribed medications are 
given, but since these medication are ancillary to the physiological maintenance, only egregious 
violations of the medication and infusion sections will serve as a reason to deem the patient not 
in compliance with the protocol.  Patients who are not maintained in these ranges but are being 
treated to return their physiological variables to normal ranges are considered in compliance with 
this protocol, as deviations are the norm for this patient population.  Therefore, a patient can only 
fail the admission protocol if he/she failed any of the other protocols or is hyperthermic for an 
extended period of time. 
 
2.2.2 Intracranial Hypertension Management Protocol 
The next portion of the admission orders deals with the intracranial hypertension protocol 
(Figure 17A).  This protocol is meant to outline the treatment of intracranial hypertension (high 
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ICP values).  Intracranial hypertension is defined in the protocol as an ICP value of greater than 
25 mmHg.  The primary point of determining adherence to this protocol is deciding on the use of 
mannitol and hypertonic saline, which are diuretic agents intended to lower ICP values by 
increasing urine output.  Often, mannitol is used as a first line of treatment for patients whose 
ICP values are above 20, but not quite sustained for any long periods at or above 25 mmHg.  
Therefore, its use indicates that the patient is aggressively being treated for elevated ICP values 
and this is the underlying intention of the protocol.  
The third protocol is the sedation protocol (Figure 18A).  Patients are paralyzed and 
sedated to minimize the risk to the patient and staff.  Often, head injury patients are combative 
and this exertion can harm the staff, as well as massively disrupt the patient’s physiology.  
Adherence to this protocol is determined by the administration of propofol, fentanyl and 
vecuronium.  If these drugs are not given, then the patient will be deemed not in adherence.   
The final protocol in the physician’s order set is the fluid replacement protocol (Figure 
19A).  Adherence to this protocol is determined by the use of normal saline, albumin, hetastarch 
and Levophed infusions.  Levophed is a trade name for norepinephrine or adrenaline.  Its use 
increases heart rate and cardiac output and therefore improves blood flow.  Any patient that is 
hypoperfused or in a hypotensive state and is not given fluid/colloidal replacement and or 
Levophed will be deemed not in compliance with the protocol. 
 
2.2.3 Importation into SAS 
Data is being imported into SAS using three separate Excel files that will combine a coded 
version of the patient and surgical demographics with a file containing the physiological data for 
 18 
each patient for the first 48 hours.  In order to achieve this goal, each patient’s individual 
physiological records are being combined into a single Excel file and then the demographic data 
is being programmed into SAS to form a single file that can be analyzed for the influence on 
Licox values.  The physiological file contains the following variables: university identification 
number, time, Licox values, serum magnesium value, fraction of inspired oxygen level, the time 
of red blood cell transfusions, mean arterial pressure, intracranial pressure, core temperature, 
cerebral perfusion pressure, and time, which will be negative before a magnesium infusion, zero 
when the infusion begins, and positive thereafter. Finally, the file includes the duration of 
magnesium infusions.  The following demographic variables will be added to the physiological 
data: magnesium dose, time from injury to magnesium dose, magnesium protocol adherence, 
injury type, injury side, Alsius, age, gender, GCS, complications, mechanism of injury, 
transportation type, emergency department drugs, Marshall score, and 3, 6, 12 and 24 month 
outcome. 
The file includes all patients.  However, the analysis is being restricted to males only, 
since there are only two females in the data set.  This same logic was applied to the coding of the 
demographic and surgical data in order to have sufficient patient numbers in each group.  The 
notable exception is the variable coding for emergency department drugs.  A code was given to 
norepinephrine administration in the emergency room despite the fact that only one patient was 
treated with norepinephrine.  The reason for coding this lone norepinephrine patient is that this 
drug is a treatment for hypotension. Patients who are hypotensive on admission often suffer 
secondary hypoxic events that would influence Licox levels.  Injury type comprises the main 
injury types, which for this patient population are subarachnoid hemorrhages (SAH), subdural 
hemorrhages (SDH), or combined in the case of multiple injuries.  Intracranial contusions are not 
 19 
considered for entry because of the great variability among the patients.  The complications 
variable is being coded as either nonexistent, non-neurological or neurological in nature.  This 
variable is limited by the fact that while the complicating event is noted, the time of the 
complication is not.  Since the time of each complication is vital to any influence this variable 
would have on Licox values, this variable will not be considered for inclusion in the model.  
There are three mechanisms of injury considered: motor vehicle accidents, motorcycle accidents 
and other.  The surgical variable will be dichotomized to none/non-neurological sugery, or a 
surgical procedure involving the brain.  Procedures performed on the brain are most likely to 
have a direct effect on cerebral oxygen tension values, and since these are multiple trauma 
patients, multiple surgeries are likely to occur making multiple coding difficult in this small 
patient population. 
2.2.4 Statistical Modeling of the Data 
The lack of females in this data set makes analysis of the female response to magnesium after 
brain injury impossible.  Also, there is a known disparity in neurological outcome between men 
and women after brain injury (Farace and Alves 2000).  Further complicating the matter is the 
large disparity in age between the women.  One woman is 43 years old and the other is 16, 
intimating that the estrogen levels in these women could be wildly different and the corollary 
being that both their brain and body chemistries will be completely different.  There is also 
evidence that the effects of serum magnesium vary between men and women (unpublished data).  
In addition, there may be gender differences in magnesium metabolism after head injury,   as 
women have significantly lower magnesium levels than their age- and injury-matched male 
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counterparts (unpublished data).  Therefore the analysis for this data set will be restricted to the 
males in the population.   
Analysis of the data set is complicated by the fact that cerebral oxygen levels may vary 
by the complexity of the patients’ injuries and medical care and by unmeasurable variables like 
genetic variation.  In planning the analysis of this data set there were three models types 
considered potentially useful.  General estimating equations (GEE) specify marginal models, 
which allow for generalizing the results of the analysis to an entire population (Ballinger 2004).  
Also, GEE models can be employed with data a continuously distributed response variable 
(Fitzmaurice et al. 2004).  Finally, these models are robust against misspecification of both the 
distribution of the response variable and the correlation structure of the model (Ballinger 2004).  
The major problem with GEE models as it pertains to this data set is the requirement that missing 
data be missing completely at random (MCAR) (Ballinger 2004).  However, missing values in 
this data set are often the result of the conditions under which they occur.  A patient who is 
suffering from an epileptic seizure will have nonsensical or missing oxygen values that are 
interspersed with data that look completely normal.  Missing data in this data set are also 
commonly caused by bedside procedures that are the direct result of low cerebral oxygen values.  
Therefore, since the missing values of this data set are not MCAR, GEE models can not be used 
for this data set. 
The next consideration for modeling this data was to use time series analysis.  Of the 
different types of times series analysis available, time series cross section regression seemed the 
most applicable to the analysis goals of this study.  This type of time series analysis allows for 
the modeling of both fixed and random effects (SAS Institute 1999).  The major drawback is that 
balancing is required to for the time series for each cross section, and the time period for the 
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cross section variable must be the same for all time series (SAS Institute 1999).  This is not the 
case in this data set.  Patients are routinely removed from the unit for surgical and diagnostic 
procedures. Thus, these data are quite unbalanced.  
The final model considered for this data set, and the one that will be used, is linear mixed 
modeling.  Mixed models allow for the use of both fixed and random effects and the 
specification of the correlation structure (Fitzmaurice et al. 2004).  In addition, these mixed 
models allow for the analysis of continuous dependent variables, which is of primary importance 
for this analysis given the nature of cerebral oxygen values.  Linear mixed model regression 
assumes that the error terms and random effects are normally distributed with a mean of zero. 
Additionally, the random effects are assumed independent for each person and for the error terms 
(Laird and Ware 1982).  The requirement for normally distributed residuals is a problem for the 
analysis of these data.    Previous attempts to analyze minute by minute physiological data have 
shown that the residuals are often non-normal.  The primary problem leading to this non-
normality is the extreme kurtosis that is often associated with this type of data.  The data tend to 
cluster around a central range of values (Figure 9).  A variety of different transformations, 
including log and power transformations, were done on this data set in order to obtain normal 
residuals.  However, none of the transformations were able to produce normalized residuals.  
Since the non-normality of the residuals will affect the various model p-values, the results of this 
study must be interpreted cautiously. 
Since the use of cerebral oxygen monitors is still relatively new, all relevant variables 
were considered for inclusion in the model.  The first step in the modeling process was to model 
Licox values against magnesium infusion and time, thus giving a baseline estimate of the effect 
of magnesium dosing on Licox values (Figure 6).   The next step was to begin building the final 
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adjusted model for the data set.  Age and GCS have a known association with outcome after 
severe head injury.  There is, however, no evidence of an effect for either of these variables on 
cerebral oxygen levels (Bullock et al. 1995).  Therefore these variables were not considered for a 
priori inclusion in the model.  Also, while considering physiological variables to include in the 
model, MAP and ICP were excluded due to their relationship with CPP.  The use of CPP allowed 
for the effects of ICP and MAP to be accounted for while avoiding any potential problems with 
colinearity. The variables that were considered for inclusion in the model are as follows: FIO2, 
CPP, the magnesium dose, the type of injury, the side of the brain where the injury is located, 
GCS, age, Marshall score, surgery, complications, adherence to the magnesium, ICP, sedation 
and fluid replacement protocols (Table 2).    The data were first modeled using an unstructured 
correlation structure and upon examining the correlation matrix, an autoregressive correlation 
structure appeared to be appropriate for the data. Therefore the data were modeled using a 
random intercept and an autoregressive correlation structure.  For the magnesium infusion 
variable the model estimated a parameter for periods when infusion did not occur and periods of 
magnesium infusion were taken as the baseline of the variable. 
 
E(Yij ׀bi) =  β1 + β2Mginfusionij + β3Timeij + bi + eij 
Figure 6 The Equation for Base Model for Licox Values 
This equation shows the mean Licox response for the base model for the ith individual at the jth time 
adjusted for magnesium infusion and time.  The model assumes random subject effects (bi) and error terms 
(eij) are both normally distributed with a mean of zero.  Also the model assumes that the random subjects 
effects are independent for each subject and for the error terms.  β1= intercept parameter estimate; β2= 





Table 2 Description of Variables Considered for the Final Model 













Fluid protocol Adherence to fluid replacement  protocol: yes or no binary  
In considering a variable for inclusion in the model a p value of 0.15 or less was 
determined to be sufficient for the variable to be included in the adjusted model.  If however, 
after modeling, the variable was not significant at a 0.05 level then it would be dropped from the 
final adjusted model.  Each variable that was considered for inclusion was modeled separately 
with the magnesium infusion and time variables.  After this process, the variables GCS, CPP, 
time FiO2 and magnesium infusion all had p values less than 0.15.  All of these variables were 
placed into a model and the variable GCS was not significant at the 0.05 level and therefore was 
dropped from the model. Utilizing this stepwise model building approach, the variables included 
in the final model were time, FiO2, CPP, time, the time of magnesium infusion and the 
magnesium dose given (Figure 7).  All of these variables were highly significant in the model 






E(Yij ׀bi)=     β1 + β2Mginfusionij + β3Timeij+  β4CPPij + β5FiO2ij + bi + eij 
Figure 7 The Equation for the Final Model of Licox Values 
This equation shows the mean Licox response for the final adjusted model for the ith individual at the 
jth time adjusted for mangnesium infusion, time, CPP and FiO2.  bi = random subject effects eij =error term  
β1= intercept parameter estimate; β2= magnesium infusion parameter estimate; β3= time parameter estimate; 
β4= CPP parameter estimate; β5= FiO2  parameter estimate. 
 
The magnesium dose was modeled separately due to the variation in magnesium doses 
given to the patients and the relationship of the magnesium dose to the magnesium infusion 
variable.  The same stepwise variable selection process used for the magnesium infusion model 
was done for the magnesium does model.  Only CPP and FiO2 levels were significant when 
modeled with magnesium dose and time after the dose.   These variables were both significant in 
the modeled with the magnesium dose and time after dose variables, and therefore were included 
in the final model. The magnesium dose is an ordinal variable that was parameterized with a 
dose of zero grams as the reference level. Estimates for two, four, six and eight milligram doses 
are therefore parameterized in reference to periods when there was no magnesium given to the 
patient (Figure 8).   
 
׀bi)=     β1 + β2Magdoseij + β3Timeij+  β4CPPij + β5FiO2ij + bi + eij E(Yij
Figure 8 The Equation for the Final Model of Licox Values 
  This model was built using the final model for magnesium infusion. This equation shows the mean 
Licox response for the magnesium dose of the ith individual at the jth time adjusted for mangnesium dose, 
time, CPP and FiO2.  bi = random subject effects eij =error term  β1= intercept parameter estimate; β2= 
magnesium dose parameter estimate; β3= time parameter estimate; β4= CPP parameter estimate; β5= FiO2 
parameter estimate. 
 
Outliers occurred frequently in some patients in this study.   Any value that is greater 
than the sum of the upper quartile and one and one half times the interquartile range, or less than 
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the lower quartile minus one and one half times the interquartile range is considered an outlier 
(Rosner 2000). In this data set the upper quartile of Licox values if 37mmHg and the lower 
quartile is 17 mmHg, giving an interquartile range of 20. Since values below the lower quartile 
range and negative and therefore impossible, Licox values above 68 mmHg will be considered 
outliers.  The vast majority of outliers in this data set come from three patients who had 
prolonged periods of Licox levels above 68 mmHg.  Therefore, in order to determine the 
influence outliers had on the modeling of this data, these three patients were removed from the 
data set and analysis was redone. These three patients received the same standard care as all 
other patients in this study, and there is no physiological reason to doubt the validity of these 
outliers.  Therefore, these patients were not dropped completely from this study. 
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3.0  RESULTS 
The focus of this study was to investigate the impact of magnesium infusion on a male 
population that had suffered a traumatic brain injury.  The patients in this data set were white 
males between the ages of 18 and 51 (Table 3).  These patients were mostly injured in motor 
vehicle accidents, requiring helicopter transport to PUH.  They tended to have multiple 
contusions and hematomas of the brain, with some patients even presenting with the rare and 
commonly more lethal epidural hematomas (Table 4).  Nine of the 17 patients had prior medical 
histories or multiple organ traumas that complicated their course of care.  The presence of drugs 
and alcohol were confirmed by positive toxicology screenings on two of the patients in this data 
set (Table 5).  Of the 17 patients in the data set, 9 had emergent brain surgery and 8 of these 9 
patients underwent other surgical procedures due to the extent of their injuries (Table 6).  The 
majority of patients were given magnesium within 24 hours of their injuries and five patients 
received multiple doses of magnesium (Table 7).  Overall protocol adherence was excellent for 
all protocols except the magnesium protocol.  The majority of patients were not dosed according 
to this protocol (Table 8).  Five of the 17 patients in this study died, two patients were lost to 







Table 3 Overall Demographic Breakdown of the Population 
Variable Categories N % 
Failure of Protocol Compliance Magnesium Replacement 12 54.5 
 Admission 1 5.9 
 ICP 2 11.8 
 Sedation 0 0 
 Fluid Replacement 6 35.3 
Injury Type SDH 6 35.3 
 SAH 6 35.3 
 Complex 5 29.4 
Injury side Right 4 23.5 
 Left 5 29.4 
 Bilateral 8 47.1 
Mechanism of Injury Car 8 47.1 
 Motorcycle 5 29.4 
 Other 4 23.5 
Dose of Magnesium Given 2 3 13.6 
 4 9 40.9 
 6 5 22.7 
 8 5 22.7 
Age 18 to 30 11 64.7 
 31 to 49 4 23.5 
 50< 2 11.8 
GCS 3 to 5 7 41.2 
 6 to 8 9 52.9 
 Missing 1 5.9 
Race White 16 94.1 
 African American 1 5.9 
Prior Medical History    
Lung Disease yes 1 5.9 
 no 16 94.1 
Surgery yes 2 11.8 
 no 15 88.2 
Trauma yes 1 5.9 
 no 16 94.1 
Psychiatric Disorder yes 4 23.5 
 no 13 76.5 
Kidney Disease yes 1 5.9 
 no 16 94.1 
Smoker yes 3 17.6 





Table 4 Primary Head Injury Diagnosis and Marshall Score 
UID Primary Brain Injury Mrshall Score
467 right frontal contusion and SDH right perietal SAH 3
472 right frontal and temporal contusion bilateral SAH 2
474 left SDH 2
485 Bilateral SDH 3
518 left SDH 3
541 right temporal and bilateral frontal contusions with left SDH in frontoperiatal region 2
547 left frontal and temporal contusions with SAH over same region Not Scored
548 right periatal contusion with SAH 2
555 SAH over both lobes Not Scored
575 Bilateral contusions with SDH 2
576 Bilateral SAH 2
582 Occipital and perietal SDH Not Scored
586 Left frontal contusion with SAH Not Scored
592 depressed left temporal fx with left frontoperietal contusion and temporal EDH Not Scored
596 right SAH and right perietal SDH Not Scored
616 extraaxial right frontal contusion (epidural) with various regions of SAH and SDH Not Scored
621 bilateral frontal lobe contusions with left frontal epidural contusion and SAH Not Scored  
Shown here are the primary injury descriptions of the study population and Marshall Scores for each patient.   
SAH=subarachnoid hematoma; SDH=subdural hemotoma; EDH=epidural hemotoma.  A Marshall score is a 









Table 5 Patient complications 
UID Preexisting and Post Injury Complications Alcohol Use Drugs Use
467 Diabetic No No
472 Moved after OR.  Dr. Kassam saw pt.  Delay of surgery to r/o death. unknown unknown
474 Ruptured spleen, L Wrist & shoulder Fx. Yes No
485 Pt. cooled from 39 to 37.  GCS 4.  Cooling Times unknown. Multiple facial fractures & pneumothorax. unknown unknown
518 None unknown unknown
541 None unknown unknown
547 None unknown No
548 SIADH No No
555 None unknown unknown
575 None unknown No
576 Post Surgical Menigitis unknown No
582 Massive brain swelling No No
586 Diabetic unknown No
592 None unknown unknown
596 None unknown unknown
616 Bilateral Hip Replacements unknown No
621 Bipolar unknown Yes
 
The above table contains information on patient complications, drug and alcohol screenings and emergency 
department medications.  SIADH stands for Syndrome of Inappropriate Antidiruetic Hormone a condition 




















Table 6 Surgeries Performed on the Patient Population 
Uid Surgerical Procedures Surgical Comment
467 Evacuated Hematoma
467 Diagnostic Perotoneal Lavage
467 Chest tube
472 Lobectomy Right Frontal
472 Craniofacial repair Severl ENT procedures
472 Evacuated Hematoma Craniotomy
472 Lobectomy Right temporal
547 Evacuated Hematoma
547 Remove bone flap
555 Diagnostic Perotoneal Lavage Clarion Hospital
555 Chest tube pneumothorax
582 Lobectomy Right Frontal and Temporal 
582 Evacuated Hematoma Temporal and Frontal





592 Lobectomy left temporal / parietal
592 Elevate depressed skull fracture
592 Craniofacial repair
592 Laparotomy open reinsertion of peg tube






































Table 7 Magnesium dosing in the patient population. 
 UID magnesium dose TimeLag from Injury to Mg Dose Initial Serum Mg
































582 8 11.5 1
586 8 8



















General demographics for magnesium dosing in the patient population.  This table shows the time to 
magnesium intervention and the dose of magnesium given in the study population.  For some patients more 
than one dose of magnesium was given within the 48 hour period of observation.  The serum mg variable is 












Table 8  Protocol Adherence in the Study Population 
UID Dose magnesium protocol admission protocol icp protocol sedation protocol fluid protocol
467 1 no:dose too low/time yes yes yes yes
472 1 no:dose too high yes yes yes yes
472 2 no:dose too low
474 1 no:dose too low no:elevated temperature yes yes yes
474 2 no:dose too low
485 1 no:dose too high yes yes yes yes
518 1 no:dose too low
518 2 yes yes no yes yes
541 1 no:dose too low yes no: no mannitol given yes no: no levophed
547 1 no:dose too low yes yes yes yes
548 1 yes yes yes yes yes
555 1 no:dose too low yes yes yes no: no levophed
575 1 yes yes no: no mannitol given yes no: no levophed
576 1 yes yes no: no mannitol given yes no: no levophed
582 yes yes yes yes
586 1 yes yes yes yes yes
592 1 yes yes yes yes yes
596 1 no:dose too low yes yes yes yes
596 2 no:dose too low
616 1 no:dose too low yes yes yes yes
616 2 yes
621 1 no:dose too low no: hypertension yes yes yes
Protocol adherence in the study population.  Patients were determined to not be in protocol adherence if they 
had not been given indicated medications, interventions, or correct dosages of medications the protocol 



















Table 9 GOS Scores for Patient Population 
UID 3 Month GOS 6 Month GOS 12 Month GOS 24 Month GOS Days till Death
467 1 1 1 1 3
472 1 1 1 1 8
474 3 90 90 90
485 1 1 1 1 3
518 3 4 4 90
541 5 5 5 90
547 4 3 3 90
548 4 4 4 5
555 2 3 3 90
575 3 92 5 5
576 1 1 1 1 12
582 1 1 1 1 3
586 3 3 3 90
592 90 90 90 90
596 4 4 90 90
616 5 5 5 90
621 96 96 96 96
 
 
GOS scores for the population.  Patient outcomes at 3, 6, 12, and 24 months.  Codes are as follows 90 = 
patient lost to follow up; 92 = unable to assess; 96 = patient refused continued participation. 
 
3.1 DATA ANALYSIS 
The data were first modeled by constructing the baseline model with the independent 
variables time and magnesium infusion time.  The residuals were not normal in the data set for 
all models due to a tendency for Licox values to cluster in the 20 to 30 mmHg range (Figure 9 
and Figure 10).  The model showed a very slight decrease in Licox values when a magnesium 
infusion occurred.  Modeling showed that Licox was increased by 3.935 mmHg during periods 
when no magnesium infusions were occurring (Figure 11, Table 10). This decrease is not 
clinically significant, as Licox values can fluctuate by as much as five millimeters of mercury per 
minute or more during the normal course of a patient’s stay in the NICU. 
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Figure 9  Histogram of Licox Values Showing Skewness and Extreme Kurtosis. 
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Figure 11 Boxplot of Licox Values by Magnesium Infusion Variable 
The parameter estimate for the time after a magnesium infusion is extremely small. However, it 
is positive, suggesting that as time after an infusion progresses, Licox values increase (Table 10).  
Since the time variable is constructed as a minute measurement, it could have a significant 
impact on Licox values as the patient progresses over the two day period of this study.  The fact 
that the parameter estimate is positive indicates that magnesium infusion are associated with 







  Table 10 Results of Modeling the Licox Data by Magnesium Infusion 
Variable Beta Standard 
Error 




L S Means 
Base Model       
intercept 24.309 3.151 <0.0001 17.756 30.862  
Mginfusion 0 3.935 0.282 <0.0001 3.383 4.488 28.616 
Mginfusion 1      24.681 
Time (minutes after infusion) 0.001 0.0001 <0.0001 0.0005 0.001  
Autoregressive Covariance 216.92 66.948 0.0006    
Final Model       
intercept 12.015 3.251 .00014 5.246 18.785  
Mginfusion 0 2.812 0.367 <0.0001 2.094 3.532 27.698 
Mginfusion 1      24.886 
Time (minutes after infusion) 0.001 0.001 <0.0001 0.0005 0.001  
FiO2 -0.039 0.009 <0.0001 -.0559 -0.022  
CPP 0.200 0.007 <0.0001 0.185 0.214  
Autoregressive Covariance 214.57 66.958 0.0007    
Final Model (Outlier  Patients 
Removed) 
      
intercept 8.372 2.892 0.01 2.296 14.448  
Mginfusion 0 0.045 0.257 0.861 -0.459 0.549 23.191 
Mginfusion 1      23.146 
Time (minutes after infusion) 0.0001 0.0001 0.441 -0.0001 0.0003  
FiO2 0.020 0.007 0.004 0.007 0.034  
CPP 0.191 0.005 <0.001 0.181 0.201  
Autoregressive Covariance 150.31 50.68 0.0015    
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Table 11 Results of Modeling the Licox Data by Magnesium Dosage 
Variable Beta Std Error P Value Lower CL UpperCL LS Means 
Base Model       
intercept 28.105 3.187 <0.001 21.478 34.731  
Magdose=0      28.365 
Magdose=2 4.956 1.152 <0.001 2.699 7.214 33.321 
Magdose=4 3.617 0.479 <0.001 2.679 4.555 31.982 
Magdose=6 -10.912 0.541 <0.001 -11.972 -9.853 17.453 
Magdose=8 -7.500 0.470 <0.001 -8.417 -6.575 20.869 
Time (minutes after infusion) 0.0005 0.0001 <0.001 0.0003 0.0007  
Autoregressive Covariance 223.11 68.922 0.0006    
Final Model       
intercept 15..301 3.305 0.0001 8.429 22.174  
Magdose=0      26.879 
Magdose=2 8.980 1.352 <0.001 6.330 11.630 35.859 
Magdose=4 8.500 0.665 <0.001 7.197 9.802 35.378 
Magdose=6 -7.804 0.770 <0.001 -9.313 -6.295 19.075 
Magdose=8 -9.772 0.541 <0.001 -10.832 -8.713 17.106 
Time (minutes after infusion) 0.0004 0.0002 0.0296 0.00004 0.0007  
FiO2 -0.045 0.009 <0.001 -0.062 -0.027  
CPP 0.191 0.007         <0.001 0.176 0.206  
Autoregressive Covariance 223.68 69.680 0.0007    
Final Model (Outlier Patients Removed)       
intercept 7.605 3.101 0.025 1.089 14.121  
Magdose=0      22.986 
Magdose=2 -9.614 1.206 <0.001 -11.978 -7.251 13.372 
Magdose=4 8.189 0.419 <0.001 7.367 9.011 31.175 
Magdose=6 -9.321 0.551 <0.001 -10.401 -8.241 13.665 
Magdose=8 -1.913 0.386 <0.001 -2.670 -1.157 21.073 
Time (minutes after infusion) -0.0003 0.0001 0.01 -0.001 -0.0001  
FiO2 0.045 0.007 <0.001 0.0307 0.058  
CPP 0.181 0.005 <0.001 0.171 0.191  
Autoregressive Covariance 175.36 59.0337 0.0015    
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 The parameter estimate for magnesium infusions in the base model was 3.935.  In the 
adjusted model, the value for the parameter estimate dropped to 2.812.  This is once again a 
clinically insignificant drop in Licox values.  It is also surprising that the adjusting for FiO2 and 
CPP levels did not have a greater influence on the parameter estimate for magnesium infusions.   
There is a slight decrease in CPP levels during a magnesium infusion.  This is consistent with the 
know properties of magnesium as a vasodilator (Figure 12).  The fact that both Licox and CPP 
levels show a mild and not a profound decrease during a magnesium infusion supports the theory 




Figure 12 Boxplot of CPP values by Magnesium Infusion Status. 
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 The time after magnesium infusions variable was not affected by adjusting for either 
FiO2 or CPP in the final model.  Both the base and final adjusted model show that Licox values 
increase as the time after a magnesium infusion progresses.  There was a positive correlation 
with time and CPP levels during both periods of magnesium infusion as well as periods without 
an infusion (Figure 13 and 14).  Since CPP is a measure of large vessel perfusion, the increase in 
CPP over time indicates that the large blood vessels of the brain are not dilating in response to 
magnesium infusions.  
 
 Cerebral Perfusion Pressure 
Figure 13 Scatter Plot of Licox Values Versus CPP Values During Periods Without Magnesium Infusions. 
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Cerebral Perfusion Pressure 
 
 Figure 14 Scatter Plot of Licox Values Versus CPP Values During Magnesium Infusions 
 
 
A base model was fit for the magnesium dose given to each patient.  In this model 
patients with doses of six or eight grams showed the largest response to magnesium.   The 
parameter estimates for the six and eight gram dosing groups were -10.912 and -7.500 
respectively.  This is a clinically significant drop in Licox values, given that the normal range is 
20 to 30 mmHg (Table 11).  The large decreases in Licox values in the six and eight gram dosing 
groups indicates that there is an optimal dose for magnesium.  If magnesium is given to the 
patient is in excess of this optimal dose, it could induce tissue hypoxia.  
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 The parameter estimate for time after magnesium infusion was again positive, but of 
smaller magnitude in this model compared to the model for magnesium infusion.  The time after 
magnesium infusion variable was fit in the same manner as in the magnesium infusion model as 
a continuous variable fit for every minute of observation on the unit.  The smaller parameter 
estimate for the time after a magnesium infusion in this model compared to the magnesium 
infusion model is due to the separate modeling of the patients by dose.  Decreases in Licox 
values in the six and eight gram dosing groups are negatively influencing the parameterization of 
the time after magnesium infusion variable.   
In the final adjusted model there were clinically relevant changes in tissue oxygenation 
across all dosing groups.  The pattern of lower Licox values in those patients given six or eight 
gram doses of magnesium were also seen in the final adjusted model.  Parameter estimates for 
the six and eight gram dosing groups were -7.804 and -9.772 respectively (Table 11).  In those 
patients receiving two and four gram doses, the parameter estimates were 8.980 and 8.500 
respectively.  These results indicate the impact magnesium has on vasodilation, and therefore 
brain tissue oxygen levels are dose dependent (Figure 15).  This model supports the results of the 
base model, which also showed a dose dependent effect.  These results show that lower doses of 




 Figure 15 Boxplot of Licox Values by Dose of Magnesium Infused. 
 
The parameter estimate for the time after magnesium infusions was relatively unchanged 
in the final model.  The parameter estimate went form 0.0005 to 0.0004 in the final model.  As in 
the final model for magnesium infusion, adjusting for FiO2 and CPP levels has almost no affect 
on the time after magnesium infusions.  Overall however, there is still an increase in Licox 
values after a magnesium infusion.  It is possible given how magnesium is infused in this patient 
population, that there is an early decrease in Licox values in the six and eight gram dosing 
groups followed eventually by a more gradual recovery of tissue oxygen levels. 
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There were three patients in this data set that had prolonged periods of outlying Licox 
values.  These patients had an influence on the parameterization of both the magnesium infusion 
and dose models.  In the magnesium infusion model with these patients removed there was 
almost no difference in the Licox values with or without magnesium infusions.  The magnitude 
of the parameter estimate for time after an infusion was greatly reduced, but still positive. In the 
magnesium dose model without these patients there is still an indication that there is an optimal 
dose for a magnesium infusion after head injury.  This parameter estimate for the two gram 
dosing group was profoundly altered, but this was the smallest dosing group and the removal of 
patients from this group has a larger effect on the parameter estimate.  The parameter estimate 
for time after magnesium infusions in this model was negative, indicating that the prolonged 








4.0  DISCUSSION 
There was little variation in Licox values during a magnesium infusion.  The decreases in Licox 
values during a magnesium infusion were not clinically relevant in any analysis of the data set.  
Since the magnesium is being infused through a central subclavian line, the results of this study 
indicate a lack of effect by magnesium on large blood vessel vasodialtion.  This is consistent 
with clinical evidence of magnesium use in preeclamptic women (Belfort et al. 1999).  If large 
blood vessels were being dilated due to magnesium, there should be a profound effect on the 
oxygen levels reaching the brain tissue.  Not only was this not seen, but when outliers were 
removed from the data, there was almost no change in Licox values due to a magnesium 
infusion.  There was no dramatic reduction in Licox values in any of the models of magnesium 
infusion.  So it is safe to conclude that large blood vessels were not either at the point of 
magnesium entry into the body or at vessels distal to the point of infusion. 
 In the magnesium dose models there appeared to be a dose dependent change in Licox 
values.  In the base and final adjusted models, patients receiving six and eight gram doses had 
large decreases in their Licox values during a magnesium infusion.  Also, the two and four dose 
groups had significant improvements in their Licox values in the adjusted model.  These results 
indicate that lower doses of magnesium are optimal in this patient population.  This was 
especially true for the four gram dose group, which had a consistent increase in Licox values 
across all models.  Therefore, low doses of magnesium may be therapeutic for brain tissue 
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hypoxia.  Futher investigation of these results is warranted, but is beyond the scope of this study, 
as it would involve the use of more sophisticated time series analysis models in order to 
determine the initiation and duration of the effect. 
 The magnitude of the time after magnesium infusion variable was relatively unchanged 
across both the magnesium infusion and magnesium dose models.  The most significant change 
was seen across the magnesium infusion and magnesium dose models. This is due the separation 
of patients by dosing category and the subsequent drop in Licox values at higher dosing levels.  
The fact that oxygen levels increased in both models with time shows that magnesium is having 
a prolonged vasodilation effect on this population. 
Licox values increase with CPP in both the magnesium infusion and dose models. 
However, there are periods when the patient has adequate perfusion yet poor oxygenation of the 
brain tissue, as well as periods when patients have adequate oxygenation during periods of poor 
tissue perfusion.  These apparently anomalous results may represent periods of loss of cerebral 
autoregulation or possibly periods of cortical spreading depression (Werner and Engelhard 2007; 
Strong et al. 2007). Both loss of autoregulation and cortical spreading depression are likely to 
occur in these patients, and further research is necessary to determine how these events impact 
Licox values. The parameter estimates for CPP are not large, mostly due to the fact that it is a 
continuous variable in the model.  However, large changes in the CPP levels can and often do 
occur in these patients and these fluctuations would have enormous implications for tissue 
oxygenation based on these models.   
Licox values decreased slightly when the FiO2 levels were raised in both of the final 
adjusted models.  FiO2 was fit as a continuous variable and therefore the parameter estimate is 
small.  It was surprising that the effect that was seen was negative in the final adjusted model.  
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This indicates that magnesium is increasing oxygen delivery to the tissue despite a decrease in 
the inspired oxygen.  Therefore, increases in FiO2 during a magnesium infusion may not be 
warranted, for especially those patients receiving a four gram dose of magnesium, which may 
lead to an over abundance of oxygen in the tissue.  These luxuriant oxygen levels can be 
potentially harmful.  It could lead to oxidative cell damage and even death as oxygen is 
radicalized by aberrant cellular metabolism.  The small negative effect of FiO2 may have another 
possible cause, as it is not uncommon for there to be no response or a lag in response by the 
Licox probe to changes in FiO2 levels.  It is not clear what the exact cause of this lagging or 
absent response is, but it is likely related to damage to the vasculature of the brain itself.  Periods 
of irregular blood flow are common after brain injuries due to a phenomenon called vasospasm 
(Oertel et al. 2005).  These uncontrolled contractions of the brain vasculature influence the 
delivery of blood to all regions of the brain (Oertel et al. 2005).  Since there is an inflammatory 
reaction in the vasculature associated with vasospasm, it is not inconceivable that entire regions 
of the brain are under perfused or even deprived of blood during vasospasm (Oertel et al. 2005).  
This of course would be more likely to occur in patients who have multiple brain injuries as well 
as those patients with a poor neurological prognosis.  The relationship between Licox and FiO2 
could also indicate a surprising preservation of vasculature carbon dioxide reactivity by this 
patient population (Werner and Engelhard 2007).  The fact that there are more outliers in Licox 
values at the lower levels of FiO2 support this theory (Figure 12).  Since loss of carbon dioxide 
reactivity occurs early after trauma it is likely to occur during the time period of this study 
(Werner and Engelhard 2007).  Carbon dioxide reactivity is likely to have a significant effect on 
this data, as it would influence Licox values especially for those patients having a poor 
neurological outcome (Werner and Engelhard 2007). 
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The outliers in the Licox data were a particular problem in this data set.  The majority of 
outliers came from three of the patients in the data set, patients 547, 586 and 621.  Patient 621 
refused further participation in the study so the neurological outcome for this patient is unknown.  
Patient 586 had a GOS of 3 which did not change at any of the follow-up appointments for 
neurological testing.  Patient 547 a good three month outcome and then later deteriorated to a 
poor outcome.  Removing these patients had significant impact on both models.  The 
parameterization of the magnesium infusion, magnesium dose, time after a magnesium infusion 
and FiO2 variables was profoundly influenced by the presence of these patients.  The cause of 
the elevated oxygen levels in these patients is undetermined. Spikes in Licox values occurred 
after day one for patient 586 and intermittently through both days for patients 621 and 547.  The 
true cause of these spikes in Licox may become evident in subsequent patients, as a protocol is 
now in place to monitor for cortical spreading depression.  These patients are obviously exerting 
an influence on the conclusion of this study.  However, there is no reason to drop the patients, 
since there is no reason to doubt the validity of their data. 
The results of clinical trials in both stroke and head injury show that magnesium 
supplementation increases patient mortality and morbidity (Temkin et al. 2007; Lees et al. 2004).  
Patients who do survive a brain injury may never fully recover, and those who do often require 
intensive physical and mental rehabilitation.  This long term process places a great financial 
burden on the health care system, and a great social burden on communities due to the loss of 
productive life years that brain injury patients’ experience.  The public health significance of this 
study is that by elucidating how magnesium contributes to poor outcomes after head injury 
mortality and morbidity after brain injuries may be reduced. 
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5.0  CONCLUSIONS 
Overall, there was little change in Licox values in the magnesium infusion model when adjusting 
for time after magnesium infusions, CPP, and FiO2.  The magnesium dose model seems to 
indicate that there is an optimal dose for magnesium in head injury patients.  Both models 
provide evidence that serum magnesium dosing is not causing anoxia after head injury.  In fact, 
there is a Those patients that are extremely sensitive to the dosing are at greater risk for hypoxia, 
which will further endanger the brain tissue. 
 There was very little movement in the GOS values after the 3 month outcome test.  Only 
six patients, had a change in either direction over the 6, 12 or 24 month outcome tests.  Of these 
six patients one regressed from a 4 to a 3 and the rest improved only one point on the scale.  This 
is a very common result. Those patients surviving the injury can improve neurologically through 
the intensive rehabilitation processes they undergo, but change is often not dramatic.  This lack 
of improvement is the main reason why the prevention of secondary injuries to the brain is so 
critical after closed head trauma.  The very nature of the neural environment places brain cells in 
a very precarious position, and trauma to the brain can have necrotic effects on brain tissue that 
is distal to the injury core.    
The failures of the clinical trials with magnesium should not be ignored.  Identifying and 
understanding the mechanism by which magnesium increased mortality in brain injury trials 
might elucidate ways to decrease mortality and improve outcome after head injury.  The results 
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of this study show that magnesium can influence cerebral physiology, and therefore impact 
neurological outcome in head injury patients.  Future studies of the effects of magnesium should 
include a larger and more diverse patient population, as it is likely that the results of this study 
would have been different if a sufficient female population was available.  Also, future research 
using intensive repeated measures analysis should incorporate more dynamic statistical 
modeling. More advanced time lagged and time series models may fit this data better and 
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Figure 17A Intracranial Hypertension Management Protocol. 
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Figure 19A Fluid Replacement Protocol for Head Injury Patients 
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APPENDIX B: DATA DICTIONARY FOR SAS PROGRAM 
Data dictionary for SAS file: 
Variable     Name       Codes   
UID      UID    N.A. 
Time      Time    N.A. 
Licox value     Licox    N.A. 
Serum magnesium level   Mg    N.A. 
Fraction of inspired oxygen   FiO2    N.A. 
Blood transfusions    RBC    N.A. 
Mean Arterial Pressure   ABP_M   N.A. 
Intracranial Pressure    ICP    N.A. 
Core temperature    T1    N.A. 
Cerebral Perfusion Pressure   CPP    N.A. 
Magnesium dose    Mginfusion   0=no 
          1=yes 
Magnesium Dose    Magdose   N.A. 
Time from Injury to Magnesium Dose maglag  0=24 hours or less 
         1=25 to 48 hours 
Magnesium protocol    Magproto   0=no 
          1=yes 
Admission protocol    Admisproto   0=no 
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Variable     Name       Codes   
         1=yes 
ICP protocol     ICPproto   0=no 
          1=yes 
Sedation protocol    Sedproto   0=no 
          1=yes 
Fluid replacement protocol   Fluidproto   0=no 
          1=yes 
Injury type     Injurytype   0=SAH 
          1=SDH 
          2=combined 
Injury side     injuryside   0=left 
          1=right 
          2=bilateral 
Alsius      Alsius    0=no 
          1=yes 
 
Age      Age    N.A 
 
Gender     Gender   0=female 




 Variable     Name       Codes   
Complications     complications   0=none 
         1=nonneurological 
          2=neurological 
GCS      GCS    N.A.  
Mechanism of Injury    Mechinjury  0=Motor vehicle 
          1=Motorcycle 
          2=Other 
Transport     Transport   0=helicopter 
          1=ambulance 
Emergency department drugs   Eddrug   0=none 
          1=mannitol 
         2=norepinephrine 
Marshall score     Marsh    N.A. 
Surgery     Surgery   0=none 
1=yes 
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if uid=467  and mginfusion=1 then magdose=6 ; 
if uid=472 and mginfusion=1 then magdose=6 ; 
if uid=472.2 and mginfusion=1 then magdose=2; 
if uid=474 and mginfusion=1 then magdose=4; 
if uid=474.2 and mginfusion=1 then magdose=4; 
if uid=485 and mginfusion=1 then magdose=6; 
if uid=502 and mginfusion=1 then magdose=6; 
if uid=518 and mginfusion=1 then magdose=4; 
if uid=518.2 and mginfusion=1 then magdose=4; 
if uid=541 and mginfusion=1 then magdose=4 ; 
if uid=547 and mginfusion=1 then magdose=6; 
if uid=548 and mginfusion=1 then magdose=4; 
if uid=555 and mginfusion=1 then magdose=2; 
if uid=575 and mginfusion=1 then magdose=8; 
if uid=576 and mginfusion=1 then magdose=8; 
if uid=582 and mginfusion=1 then magdose=8 ; 
if uid=586 and mginfusion=1 then magdose=8; 
if uid=592 and mginfusion=1 then magdose=4; 
if uid=595 and mginfusion=1 then magdose=8 ; 
if uid=596 and mginfusion=1 then magdose=4; 
if uid=596.2 and mginfusion=1 then magdose=4; 
if uid=616 nd mginfusion=1 en magdose=6; a th  
if uid=616.2 and mginfusion=1 then magdose=8; 
if uid=621 and mginfusion=1 then magdose=2; 
if mginfusion =0 then magdose=10; 
maglag =.; 
if uid=467 then maglag=1; 
if uid=472 hen maglag=0; t  
if uid=472.2 then maglag=1; 
if uid=474 then maglag=0; 
if uid=474.2 then maglag=0; 
if uid=485 then maglag=0; 
if uid=502 then maglag=0; 
if uid=518 hen maglag=0; t  
if uid=518.2 then maglag=1; 
if uid=541 then maglag=1; 
if uid=547 then maglag=0; 
if uid=548 then maglag=1; 
if uid=555 then maglag=0; 
if uid=575 then maglag=0; 
if uid=576 then maglag=0; 
 63 
if uid=582 then maglag=0; 
if uid=586 then maglag=0; 
if uid=592 then maglag=1; 
if uid=595 then maglag=0; 
if uid=596 then maglag=0; 
if uid=596.2 then maglag=1; 
if uid=616 then maglag=0; 
if uid=616.2 then maglag=1; 
if uid=621 then maglag=0; 
 
magproto=.; 
if uid=467 then magproto=0; 
if uid=472 then magproto=0; 
if uid=472.2 then magproto=0; 
if uid=474 hen magproto=0; t  
if uid=474.2 then magproto=0; 
if uid=485 then magproto=0; 
if uid=502 then magproto=0; 
if uid=518 then magproto=0; 
if uid=518.2 then magproto=1; 
if uid=541 then magproto=0; 
if uid=547 then magproto=0; 
if uid=548 then magproto=1; 
if uid=555 then magproto=1; 
if uid=575 then magproto=1; 
if uid=576 then magproto=1; 
if uid=582 then magproto=1; 
if uid=586 then magproto=1; 
if uid=592 then magproto=1; 
if uid=595 then magproto=1; 
if uid=596 then magproto=0; 
if uid=596.2 then magproto=0; 
if uid=616 hen magproto=0; t  
if uid=616.2 then magproto=1; 
if uid=621 then magproto=0; 
admisproto =.; 
if uid=467 then admisproto=1; 
if uid=472 then admisproto=1; 
if uid=472.2 then admisproto=1; 
if uid=474 then admisproto=0; 
if uid=474.2 then admisproto=0; 
if uid=485 then admisproto=1; 
if uid=502 then admisproto=1; 
if uid=518 then admisproto=1; 
if uid=518.2 then admisproto=1; 
if uid=541 then admisproto=1; 
if uid=547 then admisproto=1; 
if uid=548 then admisproto=1; 
if uid=555 then admisproto=1; 
if uid=575 then admisproto=1; 
if uid=576 then admisproto=1; 
if uid=582 then admisproto=1; 
if uid=586 then admisproto=1; 
if uid=592 then admisproto=1; 
if uid=595 then admisproto=1; 
if uid=596 then admisproto=1; 
if uid=596.2 then admisproto=1; 
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if uid=616 then admisproto=1; 
if uid=616.2 then admisproto=1; 
if uid=621 then admisproto=1; 
icpproto=.; 
if uid=467 then icpproto=1; 
if uid=472 then icpproto=1; 
if uid=472.2 then icpproto=1; 
if uid=474 then icpproto=1; 
if uid=474.2 then icpproto=1; 
if uid=485 then icpproto=1; 
if uid=502 then icpproto=1; 
if uid=518 then icpproto=1; 
if uid=518.2 then icpproto=1; 
if uid=541 then icpproto=0; 
if uid=547 then icpproto=1; 
if uid=548 then icpproto=1; 
if uid=555 then icpproto=1; 
if uid=575 then icpproto=0; 
if uid=576 then icpproto=0; 
if uid=582 then icpproto=1; 
if uid=586 then icpproto=1; 
if uid=592 then icpproto=1; 
if uid=595 then icpproto=1; 
if uid=596 hen icpproto=1; t  
if uid=596.2 then icpproto=1; 
if uid=616 then icpproto=1; 
if uid=616.2 then icpproto=1; 
if uid=621 then icpproto=1; 
sedproto=.; 
if uid=467 then sedproto=1; 
if uid=472 then sedproto=1; 
if uid=472.2 then sedproto=1; 
if uid=474 hen sedproto=1; t  
if uid=474.2 then sedproto=1; 
if uid=485 then sedproto=1; 
if uid=502 then sedproto=1; 
if uid=518 then sedproto=1; 
if uid=518.2 then sedproto=1; 
if uid=541 then sedproto=1; 
if uid=547 then sedproto=1; 
if uid=548 then sedproto=1; 
if uid=555 then sedproto=1; 
if uid=575 then sedproto=1; 
if uid=576 then sedproto=1; 
if uid=582 then sedproto=1; 
if uid=586 then sedproto=1; 
if uid=592 then sedproto=1; 
if uid=595 then sedproto=1; 
if uid=596 then sedproto=1; 
if uid=596.2 then sedproto=1; 
if uid=616 then sedproto=1; 
if uid=616.2 then sedproto=1; 
if uid=621 then sedproto=1; 
fluidproto =.; 
if uid=467 then fluidproto=1; 
if uid=472 then fluidproto=1; 
if uid=472.2 then fluidproto=1; 
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if uid=474 then fluidproto=1; 
if uid=474.2 then fluidproto=1; 
if uid=485 then fluidproto=1; 
if uid=502 then fluidproto=0; 
if uid=518 then fluidproto=1; 
if uid=518.2 then fluidproto=1; 
if uid=541 then fluidproto=0; 
if uid=547 then fluidproto=1; 
if uid=548 then fluidproto=1; 
if uid=555 then fluidproto=0; 
if uid=575 then fluidproto=0; 
if uid=576 then fluidproto=0; 
if uid=582 then fluidproto=1; 
if uid=586 then fluidproto=1; 
if uid=592 then fluidproto=1; 
if uid=595 then fluidproto=0; 
if uid=596 then fluidproto=1; 
if uid=596.2 then fluidproto=1; 
if uid=616 then fluidproto=1; 
if uid=616.2 then fluidproto=1; 
if uid=621 en fluidproto=1; th
injurytype=.; 
if uid=467 then injurytype=2; 
if uid=472 hen injurytype=0; t  
if uid=472.2 then injurytype=1; 
if uid=474 then injurytype=1; 
if uid=474.2 then injurytype=1; 
if uid=485 then injurytype=1; 
if uid=502 then injurytype=1; 
if uid=518 hen injurytype=1; t  
if uid=518.2 then injurytype=1; 
if uid=541 then injurytype=1; 
if uid=547 then injurytype=0; 
if uid=548 then injurytype=0; 
if uid=555 then injurytype=0; 
if uid=575 then injurytype=1; 
if uid=576 then injurytype=0; 
if uid=582 then injurytype=1; 
if uid=586 then injurytype=0; 
if uid=592 then injurytype=2; 
if uid=595 then injurytype=0; 
if uid=596 hen injurytype=0; t  
if uid=596.2 then injurytype=0; 
if uid=616 then injurytype=2; 
if uid=616.2 then injurytype=2; 
if uid=621 then injurytype=2; 
injuryside =.; 
if uid=467 then injuryside=1; 
if uid=472 then injuryside=1; 
if uid=472.2 then injuryside=1; 
if uid=474 then injuryside=0; 
if uid=474.2 then injuryside=0; 
if uid=485 then injuryside=2; 
if uid=502 then injuryside=0; 
if uid=518 then injuryside=0; 
if uid=518.2 then injuryside=0; 
if uid=541 then injuryside=2; 
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if uid=547 then injuryside=0; 
if uid=548 then injuryside=1; 
if uid=555 then injuryside=2; 
if uid=575 then injuryside=2; 
if uid=576 then injuryside=2; 
if uid=582 then injuryside=2; 
if uid=586 then injuryside=0; 
if uid=592 then injuryside=0; 
if uid=595 then injuryside=1; 
if uid=596 then injuryside=1; 
if uid=596.2 then injuryside=1; 
if uid=616 then injuryside=2; 
if uid=616.2 then injuryside=2; 
if uid=621 then injuryside=2; 
alsius .  = ;
if uid=467 then alsius=0; 
if uid=472 then alsius=0; 
if uid=472.2 then alsius=0; 
if uid=474 then alsius=0; 
if uid=474.2 then alsius=0; 
if uid=485 then alsius=0; 
if uid=502 then alsius=0; 
if uid=518 then alsius=0; 
if uid=518.2 then alsius=0; 
if uid=541 then alsius=0; 
if uid=547 then alsius=0; 
if uid=548 then alsius=0; 
if uid=555 then alsius=0; 
if uid=575 then alsius=1; 
if uid=576 then alsius=1; 
if uid=582 then alsius=1; 
if uid=586 then alsius=1; 
if uid=592 then alsius=0; 
if uid=595 then alsius=1; 
if uid=596 then alsius=0; 
if uid=596.2 then alsius=0; 
if uid=616 then alsius=0; 
if uid=616.2 then alsius=0; 
if uid=621 then alsius=0; 
age=.; 
if uid=467 then age=18; 
if uid=472 hen age=51 t ; 
if uid=472.2 then age=51; 
if uid=474 then age=22; 
if uid=474.2 then age=22; 
if uid=485 then age=22; 
if uid=502 then age=16; 
if uid=518 hen age=37 t ; 
if uid=518.2 then age=37; 
if uid=541 then age=23; 
if uid=547 then age=40; 
if uid=548 then age=50; 
if uid=555 then age=44; 
if uid=575 then age=29; 
if uid=576 then age=28; 
if uid=582 then age=19; 
if uid=586 then age=18; 
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if uid=592 then age=21; 
if uid=595 then age=43; 
if uid=596 then age=30; 
if uid=596.2 then age=30; 
if uid=616 then age=45; 
if uid=616.2 then age=45; 
if uid=621 then age=20; 
gender =.; 
if uid=467 then gender=1; 
if uid=472 then gender=1; 
if uid=472.2 then gender=1; 
if uid=474 then gender=1; 
if uid=474.2 then gender=1; 
if uid=485 then gender=1; 
if uid=502 then gender=0; 
if uid=518 then gender=1; 
if uid=518.2 then gender=1; 
if uid=541 then gender=1; 
if uid=547 then gender=1; 
if uid=548 then gender=1; 
if uid=555 then gender=1; 
if uid=575 then gender=1; 
if uid=576 then gender=1; 
if uid=582 then gender=1; 
if uid=586 then gender=1; 
if uid=592 then gender=1; 
if uid=595 then gender=0; 
if uid=596 then gender=1; 
if uid=596.2 then gender=1; 
if uid=616 hen gender=1; t  
if uid=616.2 then gender=1; 
if uid=621 then gender=1; 
complications =.; 
if uid=467 then complications=1; 
if uid=472 then complications=2; 
if uid=472.2 then complications=2; 
if uid=474 then complications=1; 
if uid=474.2 then complications=1; 
if uid=485 then complications=1; 
if uid=502 then complications=1; 
if uid=518 then complications=1; 
if uid=518.2 then complications=1; 
if uid=541 then complications=0; 
if uid=547 then complications=1; 
if uid=548 then complications=1; 
if uid=555 then complications=0; 
if uid=575 then complications=1; 
if uid=576 then complications=1; 
if uid=582 then complications=2; 
if uid=586 then complications=1; 
if uid=592 then complications=0; 
if uid=595 then complications=0; 
if uid=596 then complications=0; 
if uid=596.2 then complications=1; 
if uid=616 then complications=1; 
if uid=616.2 then complications=1; 
if uid=621 then complications=1; 
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gcs=.; 
if uid=467 then gcs=4; 
if uid=472 then gcs=4; 
if uid=472.2 then gcs=4; 
if uid=474 then gcs=7; 
if uid=474.2 then gcs=7; 
if uid=485 then gcs=4; 
if uid=502 then gcs=4; 
if uid=518 hen gcs=7; t  
if uid=518.2 then gcs=7; 
if uid=541 then gcs=7; 
if uid=547 then gcs=7; 
if uid=548 then gcs=7; 
if uid=555 then gcs=4; 
if uid=575 then gcs=7; 
if uid=576 then gcs=4; 
if uid=582 then gcs=.; 
if uid=586 then gcs=6; 
if uid=592 then gcs=8; 
if uid=595 then gcs=8; 
if uid=596 hen gcs=8; t  
if uid=596.2 then gcs=8; 
if uid=616 then gcs=3; 
if uid=616.2 then gcs=3; 
if uid=621 then gcs=3; 
 
mechinjury =.; 
if uid=467 then mechinjury=0; 
if uid=472 then mechinjury=0; 
if uid=472.2 then mechinjury=0; 
if uid=474 then mechinjury=0; 
if uid=474.2 then mechinjury=0; 
if uid=485 then mechinjury=0; 
if uid=502 then mechinjury=0; 
if uid=518 then mechinjury=1; 
if uid=518.2 then mechinjury=1; 
if uid=541 then mechinjury=1; 
if uid=547 then mechinjury=1; 
if uid=548 then mechinjury=0; 
if uid=555 then mechinjury=0; 
if uid=575 then mechinjury=1; 
if uid=576 then mechinjury=1; 
if uid=582 then mechinjury=0; 
if uid=586 then mechinjury=2; 
if uid=592 then mechinjury=2; 
if uid=595 then mechinjury=2; 
if uid=596 then mechinjury=2; 
if uid=596.2 then mechinjury=0; 
if uid=616 then mechinjury=1; 
if uid=616.2 then mechinjury=1; 
if uid=621 then mechinjury=0; 
transport=.; 
if uid=467 then transport=1; 
if uid=472 then transport=0; 
if uid=472.2 then transport=0; 
if uid=474 then transport=0; 
if uid=474.2 then transport=0; 
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if uid=485 then transport=0; 
if uid=502 then transport=0; 
if uid=518 then transport=0; 
if uid=518.2 then transport=0; 
if uid=541 then transport=0; 
if uid=547 then transport=0; 
if uid=548 then transport=1; 
if uid=555 then transport=0; 
if uid=575 then transport=0; 
if uid=576 then transport=0; 
if uid=582 then transport=0; 
if uid=586 then transport=0; 
if uid=592 then transport=0; 
if uid=595 then transport=0; 
if uid=596 hen transport=0; t  
if uid=596.2 then transport=0; 
if uid=616 then transport=0; 
if uid=616.2 then transport=0; 
if uid=621 then transport=0; 
eddrug=.; 
if uid=467 then eddrug=1; 
if uid=472 then eddrug=0; 
if uid=472.2 then eddrug=0; 
if uid=474 hen eddrug=0; t  
if uid=474.2 then eddrug=0; 
if uid=485 then eddrug=2; 
if uid=502 then eddrug=1; 
if uid=518 then eddrug=0; 
if uid=518.2 then eddrug=0; 
if uid=541 then eddrug=0; 
if uid=547 then eddrug=0; 
if uid=548 then eddrug=0; 
if uid=555 then eddrug=1; 
if uid=575 then eddrug=0; 
if uid=576 then eddrug=0; 
if uid=582 then eddrug=0; 
if uid=586 then eddrug=0; 
if uid=592 then eddrug=0; 
if uid=595 then eddrug=1; 
if uid=596 then eddrug=0; 
if uid=596.2 then eddrug=0; 
if uid=616 hen eddrug=0; t  
if uid=616.2 then eddrug=0; 
if uid=621 then eddrug=0; 
marsh=.; 
if uid=467 then marsh=3; 
if uid=472 then marsh=2; 
if uid=472.2 then marsh=2; 
if uid=474 then marsh=2; 
if uid=474.2 then marsh=2; 
if uid=485 then marsh=3; 
if uid=502 then marsh=4; 
if uid=518 then marsh=3; 
if uid=518.2 then marsh=3; 
if uid=541 then marsh=2; 
if uid=547 then marsh=.; 
if uid=548 then marsh=2; 
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if uid=555 then marsh=.; 
if uid=575 then marsh=2; 
if uid=576 then marsh=2; 
if uid=582 then marsh=.; 
if uid=586 then marsh=.; 
if uid=592 then marsh=.; 
if uid=595 then marsh=3; 
if uid=596 then marsh=.; 
if uid=596.2 then marsh=2; 
if uid=616 then marsh=.; 
if uid=616.2 then marsh=.; 
if uid=621 then marsh=.; 
surgery =.; 
if uid=467 then surgery=1; 
if uid=472 hen surgery=1; t  
if uid=472.2 then surgery=1; 
if uid=474 then surgery=1; 
if uid=474.2 then surgery=1; 
if uid=485 then surgery=1; 
if uid=502 then surgery=1; 
if uid=518 hen surgery=1; t  
if uid=518.2 then surgery=1; 
if uid=541 then surgery=1; 
if uid=547 then surgery=1; 
if uid=548 then surgery=1; 
if uid=555 then surgery=0; 
if uid=575 then surgery=1; 
if uid=576 then surgery=1; 
if uid=582 then surgery=1; 
if uid=586 then surgery=1; 
if uid=592 then surgery=1; 
if uid=595 then surgery=0; 
if uid=596 hen surgery=1; t  
if uid=596.2 then surgery=1; 
if uid=616 then surgery=0; 
if uid=616.2 then surgery=0; 
if uid=621 then surgery=0; 
gos3=.; 
if uid=467 then gos3=1; 
if uid=472 then gos3=1; 
if uid=472.2 then gos3=1; 
if uid=474 hen gos3=3; t  
if uid=474.2 then gos3=1; 
if uid=485 then gos3=1; 
if uid=502 then gos3=1; 
if uid=518 then gos3=3; 
if uid=518.2 then gos3=3; 
if uid=541 then gos3=5; 
if uid=547 then gos3=4; 
if uid=548 then gos3=4; 
if uid=555 then gos3=2; 
if uid=575 then gos3=3; 
if uid=576 then gos3=1; 
if uid=582 then gos3=1; 
if uid=586 then gos3=3; 
if uid=592 then gos3=.; 
if uid=595 then gos3=3; 
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if uid=596 then gos3=4; 
if uid=596.2 then gos3=4; 
if uid=616 then gos3=5; 
if uid=616.2 then gos3=5; 
if uid=621 then gos3=.; 
gos6=.; 
if uid=467 then gos6=1; 
if uid=472 then gos6=1; 
if uid=472.2 then gos6=1; 
if uid=474 then gos6=.; 
if uid=474.2 then gos6=1; 
if uid=485 then gos6=1; 
if uid=502 then gos6=1; 
if uid=518 then gos6=4; 
if uid=518.2 then gos6=4; 
if uid=541 then gos6=5; 
if uid=547 then gos6=3; 
if uid=548 then gos6=4; 
if uid=555 then gos6=3; 
if uid=575 then gos6=.; 
if uid=576 then gos6=1; 
if uid=582 then gos6=1; 
if uid=586 then gos6=3; 
if uid=592 then gos6=.; 
if uid=595 then gos6=3; 
if uid=596 then gos6=4; 
if uid=596.2 then gos6=4; 
if uid=616 then gos6=5; 
if uid=616.2 then gos6=5; 
if uid 621 then gos6=.; =
gos12=.; 
if uid=467 then gos12=1; 
if uid=472 hen gos12=1; t  
if uid=472.2 then gos12=1; 
if uid=474 then gos12=.; 
if uid=474.2 then gos12=1; 
if uid=485 then gos12=1; 
if uid=502 then gos12=1; 
if uid=518 hen gos12=4; t  
if uid=518.2 then gos12=4; 
if uid=541 then gos12=5; 
if uid=547 then gos12=3; 
if uid=548 then gos12=4; 
if uid=555 then gos12=3; 
if uid=575 then gos12=5; 
if uid=576 then gos12=1; 
if uid=582 then gos12=1; 
if uid=586 then gos12=3; 
if uid=592 then gos12=.; 
if uid=595 then gos12=4; 
if uid=596 then gos12=.; 
if uid=596.2 then gos12=.; 
if uid=616 then gos12=5; 
if uid=616.2 then gos12=5; 
if uid=621 then gos12=.; 
gos24=.; 
if uid=467 then gos24=1; 
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if uid=472 then gos24=1; 
if uid=472.2 then gos24=1; 
if uid=474 then gos24=.; 
if uid=474.2 then gos24=1; 
if uid=485 then gos24=1; 
if uid=502 then gos24=1; 
if uid=518 then gos24=.; 
if uid=518.2 then gos24=.; 
if uid=541 then gos24=.; 
if uid=547 then gos24=.; 
if uid=548 then gos24=5; 
if uid=555 then gos24=.; 
if uid=575 then gos24=5; 
if uid=576 then gos24=1; 
if uid=582 then gos24=1; 
if uid=586 then gos24=.; 
if uid=592 then gos24=.; 
if uid=595 then gos24=.; 
if uid=596 then gos24=.; 
if uid=596.2 then gos24=.; 
if uid=616 hen gos24=.; t  
if uid=616.2 then gos24=.; 
if uid=621 then gos24=.; 
run  ;




proc sort data=thesis; 
by gender; 
run; 
proc mixed data =thesis covtest; 
by gender; 
class mginfusion; 
model licox= mginfusion time/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run  ;
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time fio2/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time cpp/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 




model licox= mginfusion time magdose/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time maglag/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time injurytype/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time injuryside/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run  ;
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time gcs/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time age/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time marsh/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 




model licox= mginfusion time surgery/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
class mginfusion; 
by gender; 
model licox= mginfusion time complications/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time magproto/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run  ;
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time icpproto/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time sedproto/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time fluidproto/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time fio2 cpp magdose gcs complications/corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 
proc mixed data =thesis covtest; 
by gender; 
class mginfusion; 
model licox= mginfusion time fio2 magdose cpp/ corrb cl; 
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lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / local type=ar(1); 
run; 










proc sort data= thesis; 
by gender; 
run; 
proc gplot data=thesis; 
by gender mginfusion; 
symbol v=circle c=red interpol=box; 
plot Licox*fio2; 
run; 
proc mixed data =thesis; 
by gender; 
class mginfusion; 
model licox= mginfusion time fio2 cpp/ outp =norm residual corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated /  type=ar(1); 
run  ;
proc mixed data =thesis order =internal; 
by gender ; 
class magdose; 
model licox= magdose time fio2 cpp/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=un; 
repeated / type=ar(1); 
run; 
 
proc mixed data =thesis covtest; 
by gender; 
class mginfusion; 
model licox= mginfusion time/ corrb cl; 
lsmeans mginfusion /adjust=bon; 
random intercept/subject=uid  type=ar(1); 
repeated /  type=ar(1); 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
 
proc mixed data =thesis order =internal covtest; 
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by gender ; 
class magdose; 
model licox= magdose injuryside time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose injurytype time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run  ;
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose gcs time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose age time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose marsh time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run  ;
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose surgery time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose magproto time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
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class magdose; 
model licox= magdose icpproto time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose fluidproto time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose sedproto time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose cpp time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run  ;
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose fio2 time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
repeated / type=ar(1)  ; 
run; 
proc mixed data =thesis order =internal covtest; 
by gender ; 
class magdose; 
model licox= magdose cpp fio2 time/ corrb cl; 
lsmeans magdose /adjust=bon; 
random intercept/subject=uid  type=ar(1) g; 
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